MS

ICON's World Children's Day; access and inclusion for every child, upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 30, 2023
Penta, Children's Day, FDA, Maternal health, DO, Food, ICON, Therapy, Center for Drug Evaluation and Research, MD, Bureau of Oceans and International Environmental and Scientific Affairs, Rights, Doctor of Philosophy, Drug development, UN General Assembly Resolution 60/147, Food and Drug Administration, Caregiver, University of Padua, Convention, University, Declaration of the Rights of the Child, Patient, UN, MS, Pharmaceutical industry, Research, Child

TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- ICON's Centre for Paediatric Clinical Development invites you to celebrate World Children's Day virtually with us on November 13, 2023. World Children's Day is recognised as an international coming together to advocate for, promote, and celebrate the rights and welfare of children and create dialogue and action plans to build a better world for children. First established in 1954, it also commemorates the day when the UN General Assembly adopted the Declaration of the Rights of the Child in 1959 and when the UN General Assembly adopted the Convention on the Rights of the Child in 1989.

Key Points: 
  • Attendees will learn about increasing awareness of the needs and effort behind providing access to safe and accurate dosage forms of medicines for every child.
  • The featured speakers will discuss how drug development can be expedited for children and their families to provide access to adapted medicines and innovative medicines.
  • TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- ICON's Centre for Paediatric Clinical Development invites you to celebrate World Children's Day virtually with us on November 13, 2023.
  • For more information, or to register for this event, visit ICON's World Children's Day .

Fundamentals of The Texas ERCOT Electric Power Market: Register Now for the 2 Day Industry Seminar (Houston, United States - December 7-8, 2023)

Retrieved on: 
Saturday, October 28, 2023
Knowledge, Transmission, ERCOT, Public policy, Non-wires alternatives, LTSA, IRP, Ancillary services (electric power), Erongo Battery Energy Storage System, Distributed generation, International Renewable Energy Agency, Valuation, Rensselaer Polytechnic Institute, Electricity, Bayes Business School, DER, Battery, DSM, Power engineering, MS, Energy demand management, World Bank, LMP, ISO, Doctor of Philosophy, Gas, Natural gas, Renewable energy, Electric power, Cryptocurrency, Auction, Electric battery, Economics, Wind

DUBLIN, Oct. 27, 2023 /PRNewswire/ -- The "Fundamentals of The Texas ERCOT Electric Power Market" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 27, 2023 /PRNewswire/ -- The "Fundamentals of The Texas ERCOT Electric Power Market" training has been added to ResearchAndMarkets.com's offering.
  • Gain an understanding of the dynamic Texas wholesale and retail competitive markets, and learn how these markets interface with ERCOT ISO energy auctions and ISO operations.
  • Understand, enhance and apply knowledge of the ERCOT' nodal market operations for Energy, Ancillary Services, Market Settlements, Capacity, Retail and Renewables.
  • The key wholesale and retail stakeholders and market participants are, and how their activities shape ERCOT's operations.

B. Braun of America Appoints Two Global Healthcare Leaders to its Board of Directors

Retrieved on: 
Friday, October 27, 2023
Knowledge, Digital, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Associate, Public health, Industrial engineering, Hannover Medical School, Siemens Healthineers, Lewis Galoob Toys, Inc. v. Nintendo of America, Inc., Financial Oversight and Management Board for Puerto Rico, Doctor of Philosophy, MBA, Human biology, Digital Science, Aetion, McGill University, Biostatistics, Real, Boehringer Ingelheim, Retirement, MS, University, Master of Science, Pain management, Institute of technology, Management, Alphabet, Pharmacoepidemiology, Epidemiology

BETHLEHEM, Pa., Oct. 27, 2023 /PRNewswire/ -- B. Braun of America Inc., a leader in smart infusion therapy and pain management, today announced the appointment of two new members to the company's board of directors. The appointments come as the company strengthens its focus on innovation, data and technology to deliver more tailored therapies and solutions to help healthcare providers improve patient outcomes.

Key Points: 
  • The appointments come as the company strengthens its focus on innovation, data and technology to deliver more tailored therapies and solutions to help healthcare providers improve patient outcomes.
  • Dorothee Bartels, PhD, MSc, is a global business and scientific leader with extensive experience using data analytics to improve healthcare outcomes.
  • Dr. Bartels currently serves as Chief Digital Officer at Aetion, a global leader in healthcare analytics.
  • "We are pleased to welcome these accomplished global business leaders to B. Braun of America's board," said Jean-Claude Dubacher, Chairman and Chief Executive Officer.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, October 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Bryant University, Manchester Metropolitan University, FDA, Roivant Sciences, RAS, Strategic planning, Kite Pharma, Food, Accounting, Rare, Johns Hopkins University, Johns, PwC, Investigational New Drug, European Medicines Agency, Biologics license application, Global marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Avutometinib, Celgene, Bachelor of Science, LLP, Regulation, Verastem Oncology, Assurance, Marketing, Head, Lead, Quality, Cancer, AbbVie, Patient, Consultant, MS, Regulatory affairs, Pharmaceutical industry, Management, Finance, Chemistry, Drug discovery

"These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.

Key Points: 
  • "These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.
  • This includes filing for accelerated approval for avutometinib and defactinib in LGSOC and preparing for a commercial launch of this potential first FDA-approved medicine for this patient population," stated Dan Paterson, President and Chief Executive Officer of Verastem Oncology.
  • "This strengthened executive team, combined with Verastem’s significant progress in advancing therapies across RAS pathway-driven cancers, is expected to accelerate our work to bring new therapies to patients with high unmet medical need."
  • Dan Calkins, Chief Financial Officer, joined Verastem Oncology in 2018 and has served as Vice President of Finance since September 2022.

Southeastern Grocers celebrates 104th birthday of associate and grant namesake, Romay Davis

Retrieved on: 
Thursday, October 26, 2023
Women, Men, Supermarket, Family, Convenience Store, Food, Beverage, Consumer, Retail, Woman, United States Army, Education, Morale, MS, State, Workforce, Organization, 6888th Central Postal Directory Battalion, NYU, Multimedia, Friends, The National WWII Museum, SEG, Winn-Dixie, The National, Army, Harveys Supermarkets, Online shopping, Entertainment, Southeastern Grocers

Southeastern Grocers Inc. (SEG), parent company and home of Fresco y Más, Harveys Supermarket and Winn-Dixie grocery stores, is celebrating its beloved Winn-Dixie associate and American Congressional Gold Medal recipient, Romay Davis, ahead of her 104th birthday.

Key Points: 
  • Southeastern Grocers Inc. (SEG), parent company and home of Fresco y Más, Harveys Supermarket and Winn-Dixie grocery stores, is celebrating its beloved Winn-Dixie associate and American Congressional Gold Medal recipient, Romay Davis, ahead of her 104th birthday.
  • View the full release here: https://www.businesswire.com/news/home/20231026277735/en/
    Today, Winn-Dixie hosted a special in-store celebration for its beloved associate Ms. Romay ahead of her 104th birthday on Sunday.
  • As we celebrate her 104th birthday, we hope to express our deepest gratitude for being a part of her extraordinary story.
  • A true pioneer of her time, Ms. Romay is also the namesake of SEG’s Romay Davis Belonging, Inclusion and Diversity Grant.

On Lok Strengthens Executive Leadership Team with New CFO and CSO

Retrieved on: 
Friday, October 27, 2023
Paul H. Nitze School of Advanced International Studies, Ageing, AstraZeneca, CSO, Johns Hopkins University, Health, Honeywell, University, MBA, Dignity, Blue Peter, BA, Min, Carlos Rosario International Public Charter School, Growth, School, Omnicom Group, Business, Hospital, Ernst & Young, CFO, Occidental College, Master of Science in Management, Stanford Graduate School of Business, Management, Accenture, Massachusetts Institute of Technology, MS, SAN, San Francisco Bay Area, Economics, Lok

"I am excited by the addition of both Min and Carl to our executive team," said Grace Li, CEO, On Lok.

Key Points: 
  • "I am excited by the addition of both Min and Carl to our executive team," said Grace Li, CEO, On Lok.
  • Carl Gerlach brings five decades of health care finance and executive experience in managed care, physician practices, and hospitals to On Lok.
  • He has held roles as CFO, chief executive officer, board member, and consultant for hospitals, medical groups, clinics, healthcare systems, and managed care organizations, as well as On Lok.
  • Min Chang brings more than 35 years of experience in business development, senior healthcare, and mergers and acquisitions to On Lok.

HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS

Retrieved on: 
Thursday, October 26, 2023
DSM-IV codes, Patient, DO, Sleep, Heart, Sleep disorder, Historically black colleges and universities, Education, Prader–Willi syndrome, Health, Life, Corporate Affairs, Organization, Kleine–Levin syndrome, Rare, Progress, Neurological disorder, Communes of Burundi, Caregiver, Harmony, Student, Interim, MS, University, Geisinger Health System, PWS, Diagnosis, Empathy, KLS, Pharmaceutical industry, Residential care, Nursing

"With support from a previous Patients at the Heart award, we achieved the 'Strategic Communications for Awareness' project, which fortified and expanded our patient registry and outreach endeavors.

Key Points: 
  • "With support from a previous Patients at the Heart award, we achieved the 'Strategic Communications for Awareness' project, which fortified and expanded our patient registry and outreach endeavors.
  • Progress at the Heart provides funding support for novel initiatives addressing disparities, injustices, and inequities in rare neurological disease and sleep disorder communities.
  • The next call for Patients at the Heart and Progress at the Heart award nominations will be announced next year.
  • To learn more about Patients at the Heart, please visit: https://www.harmonybiosciences.com/funding-programs/patients-at-the-heart/ .

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Retrieved on: 
Wednesday, October 18, 2023
Mass General Brigham, FDA, Harvard Medical School, Food, Neurology, HMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Multiple sclerosis, Mass, Sclerosis, Patient, Hospital, MS, Pharmaceutical industry, Brigham, Foralumab

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis.

Key Points: 
  • NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis.
  • The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences.
  • Intranasal Foralumab, a novel biologic therapy, has demonstrated remarkable potential in the management of multiple sclerosis.
  • This step significantly aligns with our mission to make innovative therapies more accessible to patients and ultimately improve their quality of life.

Garuda Therapeutics Announces the Appointment of Panteli Theocharous, Ph.D., FRCPath as Chief Therapeutics Officer

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, Pharmaceutical, Health, Stem Cells, Medical Affairs Bureau, PPD, Hematology, University, Royal Free Hospital, Cell, Malignancy, Gene, HSC, Royal College of Pathologists, Thermo Fisher Scientific, Haematopoietic system, Therapy, Patient, Hematopoietic stem cell transplantation, MS, Pharmaceutical industry, Medical device, Garuda

Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced the appointment of Panteli Theocharous, Ph.D., FRCPath as Chief Therapeutics Officer.

Key Points: 
  • Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced the appointment of Panteli Theocharous, Ph.D., FRCPath as Chief Therapeutics Officer.
  • To the role, Dr. Theocharous brings experience leading multiple hematology and oncology assets into and through clinical development and beyond.
  • He previously served as Global Head, Cell and Gene Therapy Strategy Lead at PPD, part of Thermo Fisher Scientific.
  • “As Garuda continues to advance our off-the-shelf durable blood stem cell and immune cell programs, Dr. Theocharous’ experience driving HSC-based cellular therapies across all phases of development will be invaluable,” said Dhvanit Shah, Ph.D., President and Chief Executive Officer of Garuda.

Morgan Stanley Announces Ted Pick to Become Chief Executive Officer on January 1, 2024; James Gorman to Become Executive Chairman

Retrieved on: 
Wednesday, October 25, 2023
Banking, Professional Services, Finance, Harvard Business School, Capital market, Research, Management development, Phi Beta Kappa, Investment management, NYSE, Morgan Stanley, Delhi Sikh Gurdwara Management Committee, Investment banking, Advisory board, MBA, Triple accreditation, Mental health, Equity capital markets, Middlebury College, Metropolitan, Growth, Metropolitan Museum of Art, Risk, Compensation, Institute of International Finance, Head, Institutional Security Bureau, Culture, MET, MS, Management, Security (finance), Art

The Board of Directors of Morgan Stanley (NYSE: MS) today announced that Co-President Edward (Ted) Pick will become the Firm’s Chief Executive Officer, effective January 1, 2024.

Key Points: 
  • The Board of Directors of Morgan Stanley (NYSE: MS) today announced that Co-President Edward (Ted) Pick will become the Firm’s Chief Executive Officer, effective January 1, 2024.
  • Mr. Gorman announced at the Firm’s 2023 annual general meeting of shareholders his intention to step down as Chief Executive Officer before the 2024 annual general meeting.
  • As Co-Presidents of Morgan Stanley, Andy and Dan will be invaluable leaders in helping Ted manage the Firm.
  • Pick said, “Morgan Stanley is a storied institution, and I am deeply honored to have been chosen to lead it.